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Abstract
Purpose Doxorubicin is a first-line chemotherapeutic for
breast cancer; however, it is associated with severe side
effects to non-tumoral tissues. Thus, it is necessary to
develop new therapeutic combinations to improve doxo-
rubicin effects at lower concentration of the drug associ-
ated with protective effects for non-tumoral cells. In this
work, we evaluated whether the plant-derived flavonoid
quercetin may represent such an agent.
Methods The effects of doxorubicin and quercetin as
single agents and in combination were evaluated on cell
survival, DNA and protein synthesis, oxidative stress,
migratory potential and cytoskeleton and nucleus structure
in highly invasive and poorly invasive human breast
cancer cells in comparison with non-tumoral human breast
cells.
Results In human breast cancer cells, quercetin potenti-
ated antitumor effects of doxorubicin specifically in the
highly invasive breast cancer cells and attenuated unwan-
ted cytotoxicity to non-tumoral cells. Quercetin interfered
with cell metabolism, GST activity, cytoskeleton and
invasive properties specifically in breast tumor cells com-
pared with non-tumoral breast cells. Doxorubicin induced
DNA damage in tumor and non-tumor cells; however,
quercetin reduced this damage only in non-tumoral cells,
thus offering a protective effect for these cells. Quercetin
also induced polynucleation in aggressive tumor cells,
which was maintained in combination with doxorubicin.
Conclusions By combining quercetin with doxorubicin,
an increase in doxorubicin effects was obtained specifically
in the highly invasive breast cancer cells, while in non-
tumoral cells quercetin reduced doxorubicin cytotoxic side
effects. Thus, quercetin associated with doxorubicin dem-
onstrated very promising properties for developing che-
motherapeutics combinations for the therapy of breast
cancer.
Keywords Quercetin  Doxorubicin  Breast cancer cells 
Tyrosine protein kinases  Polynucleation  Genotoxicity
Introduction
The response to breast cancer chemotherapy is dependent
on the subtype of the tumor, luminal-type breast cancer
have a lower risk of metastasis and relatively good clinical
outcome, whereas basal-type cancers are highly invasive,
progress aggressively and have a poor prognosis. The
invasive properties of cancers are dependent on epithelial
cell capacity for migration and epithelial-to-mesenchymal
transition. In this process, epithelial cells loose their epi-
thelial characteristics and acquire migratory mesenchymal
cell-like properties. Thus, for evaluating therapeutic effi-
cacy of single agents as well as combination of chemo-
therapeutics, it is necessary to evaluate them in human
mammary cells representative of these different pheno-
types. For chemotherapy, drug combinations are mostly
used [1] and presently, anthracyclines such as doxorubicin
are used in first-line treatment [2, 3].
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However, doxorubicin has limits in clinical use due to the
development of resistance by tumor cells and toxicity for
healthy tissues [3, 4]. Thus, to improve therapy regimen with
doxorubicin, it is necessary to evaluate new and more tumor-
specific doxorubicin-based combination therapies, targeting
several cellular pathways and able to reduce the concentra-
tion of drug necessary for efficacy, the emergence of drug
resistance, and the adverse side effects of chemotherapy [2].
Quercetin (3,30,40,5,7-pentahydroxyflavone) is a plant-
derived flavonoid present in the diet
which displays antioxidant, anti-inflammatory, and anticancer
properties [5–7], including in human cancers [6, 8–14]. Long-
term treatment with quercetin results in pro-apoptotic effects
that are correlated with decreased levels of GSH [15], a sub-
strate for the phase II drug-metabolizing enzymes glutathione
S-transferases (GST) that covalently link electrophilic com-
pounds with (GSH), in particular GST-P1-1/p overexpressed
in cancer, including breast cancer [16–19]. Quercetin has been
evaluated in phase I clinical trials for hematological malig-
nancies as a tyrosine kinase inhibitor without myelosuppres-
sive or other serious side effects [6]. Several experimental in
vitro and in vivo studies have evaluated quercetin in combi-
nation with classical or new anticancer drugs for breast cancer
treatment, showing synergistic effects [20–23]. In murine
models of breast cancer, quercetin reduced breast cancer cell
proliferation when combined with the polyphenols resveratrol
and catechin [21], and in combination with doxorubicin,
quercetin improved the efficacy and the therapeutic index of
doxorubicin, while decreasing doxorubicin-mediated toxicity
[22–24]. Our aims were thus to evaluate doxorubicin-based
chemotherapeutic combination with the natural compound
quercetin for human mammary cells, either cancer cells of
increasing aggressiveness or non-tumoral cells.
Materials and methods
Cells and cell treatments
MDA-MB-231 and MCF-7 cells were obtained from the
ATCC (American Tissue Culture Collection, Manassas,
VA, USA). MCF-10A cells were a gift from C. Brisken
(EPFL, Lausanne, Switzerland). MDA-MB-231 and MFC-
7 cells were grown in Dulbecco’s modified Eagle medium
(DMEM) containing 4.5 g/l glucose, 10% heat-inactivated
fetal calf serum (FCS), and penicillin/streptomycin (all cell
culture reagents were obtained from Invitrogen, Basel,
Switzerland). MCF-10A cells were grown in DMEM
medium containing 4.5 g/l glucose, 5% heat-inactivated
horse serum, and penicillin/streptomycin, supplemented
with 10 lg/ml insulin, 20 lg/ml hydrocortisone, 20 ng/ml
epidermal growth factor (EGF) and 100 ng/ml cholera
toxin (all from Sigma–Aldrich, Buchs, Switzerland).
Unless otherwise specified, cells were grown for 24 h in
48-well plates (Costar, Corning, NY, USA), and then
doxorubicin, quercetin or a combination of both, diluted
with fresh complete culture medium, was added at the
indicated concentrations for 24–72 h.
Chemicals
Quercetin (purity C98%) was obtained from Sigma–
Aldrich. Quercetin solutions were freshly prepared imme-
diately before use at 100 mM in dimethylsulfoxide
(DMSO, Sigma–Aldrich) and then diluted with cell culture
medium. DMSO concentration in cell culture medium
never exceeded 0.1%, and at this concentration, DMSO had
no effects on cell functions (results not shown). Doxoru-
bicin (Actavis, Switzerland) was obtained from the Phar-
macy of the CHUV and was dissolved at 10 mM in 0.9%
NaCl and stored in aliquots at -20C.
Determination of cytotoxicity
Following exposure to the chemicals, cell viability was
evaluated using the MTT (3-(4,5-dimethyl-2-thiazoyl)-2,5-
diphenyltetrazolium bromide, Sigma–Aldrich, 200 lg/ml
final concentration) assay, essentially as previously
described [25]. Absorbance at 540 nm was measured in a
multi-well plate reader (iEMS Reader, Labsystems, Bio-
concept, Allschwil, Switzerland), and the absorbance val-
ues of treated cells were compared with the absorbance
values of untreated cells. Experiments were conducted in
quadruplicate wells and repeated twice. Means ± standard
deviations (SD) were calculated.
Evaluation of DNA and protein synthesis
Thymidine and leucine incorporation was used to assess
DNA and protein synthesis, respectively, essentially as
previously described [25]. Briefly, following cell exposure
to the chemicals for 72 h, tritiated thymidine (3H-T)
(Amersham-Pharmacia, Glattbrugg, Switzerland, 400 nCi/
ml final concentration) or tritiated leucine (3H-Leu)
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(American Radiolabeled Chemicals, St. Louis, USA;
400 nCi/ml final concentration) was added to the cells for
4 h. Then, the cell layers were precipitated with trichlo-
roacetic acid, dissolved in sodium dodecyl sulfate in 0.1 N
NaOH and scintillation cocktail (Optiphase HI-Safe,
PerkinElmer, Beaconsfield, UK). Radioactivity was coun-
ted in a b-counter (WinSpectra, Wallac, Germany). The
radioactivity counts of treated cells were compared with
the radioactivity counts of untreated cells. Experiments
were conducted in quadruplicate wells and repeated twice.
Means ± SD were calculated.
Determination of reactive oxygen species
ROS production by cells was detected by measuring the
oxidation of dihydroethidium to ethidium by cells following
exposure to the chemicals for 72 h. After the treatments, the
cell layers were washed with PBS, and then 250 ll/well of
100 lM dihydroethidium (Sigma–Aldrich) in DMEM
without phenol red (Invitrogen) and without FCS was added
to the cell layers for 15 min at 37C in the dark. Then, the
cells were washed with PBS and lysed with 0.1% Triton
X-100 (Sigma–Aldrich) in PBS. For a positive control, the
cells were exposed for 1 h to 3 mM tert-butyl hydroperoxide
(Sigma–Aldrich) before the addition of dihydroethidium.
Ethidium fluorescence was measured in a fluorescence
multi-well plate reader (Cytofluor PerSeptive BioSystems,
BioConcept, Basel, Switzerland) at kex/kem = 485/580 nm.
Fluorescence of treated cells was compared with the fluo-
rescence of untreated cells. Experiments were conducted in
triplicate wells and repeated three times. Results were nor-
malized according to the protein content and expressed as
percentage of the control cell values. Means ± SD were
calculated. ROS production was also determined using
5-(and-6)-carboxy-20,70-dichlorodihydrofluorescein diace-
tate (DCFH-DA). Following treatments, the cell layers were
washed with PBS, and 250 ll/well of 20 lM DCFH-DA
(Invitrogen) in Hank’s buffer solution (HBSS, Invitrogen)
was added for 40 min at 37C. As positive control, cells
were exposed for 1 h to 3 mM tert-butyl hydroperoxide
before the addition of DCFH. Fluorescence of DCF was
measured in a fluorescence multi-well plate reader
(Cytofluor) at kex/kem = 485/527 nm. Experiments were
conducted in triplicate wells and repeated three times.
Results were normalized according to the protein content,
and the fluorescence of treated cells was compared with
the fluorescence of untreated cells. Means ± SD were
calculated.
Determination of cellular thiols
The monobromobimane assay was used to measure cellular
thiol concentration. Following cell exposure to the
chemicals, the cell layers were washed with PBS, and 250 ll/
well of 100 lM monobromobimane (Sigma–Aldrich) in
PBS was added at RT for 5 min in the dark. Then, the cell
layers were washed with PBS and lysed with 0.1% Triton
X-100 (Sigma–Aldrich) in PBS. For a positive control,
cells were exposed to 100 lM N-ethyl-maleimide (Sigma–
Aldrich) for 1 h before the assay. Thiol adducts were
measured in a fluorescence multi-well plate reader (Cyto-
fluor) at kex/kem = 360/460 nm. The fluorescence of trea-
ted cells was compared with the fluorescence of untreated
cells. Experiments were conducted in triplicate wells and
repeated three times. Results were normalized according to
the protein content and expressed as percentage of control
cell values. Means ± SD were calculated.
Determination of cellular protein content
Cellular protein concentration was determined using the
BCA protein assay, according the provider’s instructions
(BCA Protein Assay Kit, Pierce, Rockford, USA) using
bovine serum albumin as the standard. Experiments were
conducted in triplicates. Means ± SD were calculated.
Glutathione-S-transferase activity
The activity of GST in cell extracts was determined using
1-chloro-2,4-dinitrobenzene (CDNB) essentially as previ-
ously described [25]. Briefly, cells were grown for 24 h in
9-cm-diameter Petri dishes (BD Falcon, Basel, Switzer-
land) and exposed to the chemicals for 72 h. Then, the cell
layers were scrapped in cold pH 6.5 PBS, extracted by 4
cycles of freeze/thawing, and centrifuged at 10,000 rpm at
4C for 10 min and the supernatants were collected. After
addition of 1 mM CDNB (Sigma–Aldrich) and 1 mM of
glutathione (GSH, Sigma–Aldrich), final concentrations,
GST activity in the supernatants was determined by mea-
suring the increase in absorbance at 340 nm in a multi-well
plate reader (iEMS Reader) for 30 min at 37C. GST
activity was expressed as nM CDNB-GSH conjugates/min/
mg protein. The values of enzymatic activities of treated
cells were compared with enzymatic activities of untreated
cells. Measurements were performed in triplicates and
repeated three times. Means ± SD were calculated.
Western blot experiments
Cells were grown in 9-cm-diameter Petri dishes and
exposed to the chemicals for the appropriate times. After
the treatments, the cell layers were washed with cold PBS
and lysed in 200 ll of lysis buffer (150 mM NaCl, 2 mM
EDTA, 0.5% Triton X-100, 50 mM Tris–HCl, 2 mM
vanadate, 50 mM NaF, pH 7.2) and 10 ll of proteinase
inhibitor cocktail (Sigma–Aldrich), scraped with a cell
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scrapper, extracted by four cycles of freeze/thawing, and
centrifuged at 10,000 rpm at 4C for 10 min. Supernatants
were submitted to SDS–PAGE and transferred onto a
nitrocellulose membrane (Whatman, Dassel, Germany).
The membranes were blocked with 5% fat-free milk in
PBS, washed in 0.05% Tween-20 (Sigma–Aldrich) in PBS,
and incubated overnight at 4C with a polyclonal anti-
human GST-P1-1 rabbit antibody (Enzo Life Sciences,
Lausen, Switzerland; diluted 1:5,000 in 1% fat-free milk
0.05% Tween-20 in PBS) and then exposed for 60 min to
peroxidase-conjugated anti-rabbit antibody (Promega,
Madison, USA; diluted 1:5,000) and visualized using
chemoluminescence (ECL, GE Healthcare, Amersham,
UK). Protein tyrosine phosphorylation was determined using
an anti-phosphotyrosine monoclonal antibody (Transduc-
tion Laboratories, BD, Basel, Switzerland; diluted 1:2,500)
and peroxidase-conjugated anti-mouse secondary antibody
(Promega; diluted 1:2,500). To control for loading, the
membranes were stripped by successive incubation in 0.1 M
glycine pH 2.3, 1 M NaCl in PBS and 0.05% Tween 20 in
PBS, blocked for 1 h with 5% fat-free milk in PBS and
exposed to a polyclonal anti-human b-actin rabbit antibody
(Sigma–Aldrich; diluted 1:5,000) for 1 h at RT and treated as
described above.
Cell actin staining with fluorescent phalloidin
Cells were grown for 24 h on glass slides (Menzel-Gla¨ser,
Braunschweig, Germany). Then, the medium was changed,
and chemicals diluted with complete culture medium were
added at the indicated concentrations and the cells were
further incubated for 72 h. At the end of the treatment, the
cell layers were washed in PBS, fixed in 4% formaldehyde
for 10 min at RT, washed with PBS, permeabilized for
5 min in 0.1% Triton X-100 in PBS, and washed. Then,
200 ll of a 1% bovine serum albumin (Sigma–Aldrich) and
2.5% Oregon Green 488 Phalloidin (Invitrogen, 6.6 lM
stock solution in methanol) solution in PBS were added.
After 20-min incubation at RT, the cell layers were washed
with PBS, and 2 ml of 1 lg/ml 40,60-diamidino-2-phenyl-
indole (DAPI) (Roche Diagnostics, Rotkreutz, Switzer-
land) in PBS was added for 20 min. Slides were washed
with PBS and mounted in 20% glycerol in PBS. Fluores-
cence images were taken with a Zeiss Axioplan 2 Imaging
microscope (Zeiss) at 4009 magnification and kex/kem =
365/420 nm (DAPI) or kex/kem = 450–490/515–565 nm.
Cell migration assay
Both sides of the membrane of a two-chamber Transwell
device (6.5 mm diameter, 8.0-lm pore size polyethylene
membrane, Falcon, BD) were coated with a solution of
20 lg/ml collagen type IV (Sigma–Aldrich, 50 ll per
membrane) in 0.02 M acetic acid for 60 min, washed with
PBS, and air-dried. Cells in 100 ll complete cell culture
medium were added to the upper chamber, and 600 ll of
cell culture medium was added to the lower chamber. After
24 h of culture of the cells on the membrane, the medium
was changed, and chemicals diluted with complete culture
medium were added at the indicated concentrations and the
cells were further cultured for either 8 or 72 h. At the end
of the treatment, cells on the upper side of the membrane
were removed by swiping with a damp cotton swab. The
membrane was rinsed with PBS and stained for 10 min
with 0.05% crystal violet in 1.5% glacial acetic acid (both
from Sigma–Aldrich). After washing with PBS, cells of
four different fields of the lower side of the membrane were
counted under a microscope at a 2009 magnification.
Experiments were conducted in triplicate wells and repe-
ated twice. Means ± SD were calculated.
Comet assay
Induction of DNA strand breaks by doxorubicin and
quercetin in the human mammary cells was determined
using an alkaline single-gel Comet assay [26] with minor
modifications. Briefly, cells were grown for 24 h in a
12-well plate (Corning), and then chemicals diluted with
fresh complete culture medium were added at the indicated
concentrations and the cells were further incubated for
72 h. Cells were detached using trypsin–EDTA (TrypLE
Express, Invitrogen), and the cell suspension (800,000
cells/ml) in 1% low melting point agarose (Sigma–Aldrich)
was deposited on glass slides coated with 1% normal
melting point agarose (Eurobio, Les Ulis, France). After
5 min at 4C to allow solidification of the cell layer, slides
were immersed in lysis buffer (2.5 M NaCl, 100 mM
EDTA, 10 mM Tris–base, 1% Triton X-100, pH 10.0) for
1 h at 4C, and then a 40-min unwinding process at 4C
and electrophoresis at 300 mA and 25 V for 30 min were
performed, both under alkaline conditions (300 mM
NaOH, 1 mM EDTA, pH 13.0). Following washing with
cold PBS and cold nanopure water, slides were stained with
1 lg/ml DAPI (Roche) in PBS. Analysis of Comet
appearance was carried out with a Zeiss Axioplan 2
Imaging microscope at a 2009 magnification and kex/
kem = 365/420 nm. For each experiment, 100 cells were
analyzed twice randomly per treatment, using the Comet
assay image analysis software (Comet Visual, University
of Oslo, Faculty of Medicine, Department of Nutrition,
Oslo, Norway). Damaged cells were classified into four
classes according to the comet tail length, using the visual
scoring approach [27]. Results were expressed as percent-
age of damaged DNA in treated cells compared with non-
treated cells. Experiments were conducted in duplicates
and repeated twice. Means ± SD were calculated.
1164 Cancer Chemother Pharmacol (2011) 68:1161–1172
123
Statistical analysis
Results were subjected to computer-assisted statistical
analysis using the ANOVA one-way analysis of variance
and the Tukey–Kramer single-step multiple comparison
procedure as a post test. Differences of P \ 0.05 were
considered significant. For all experiments and each cell
line, treatment effect was first evaluated in treated versus
untreated cells, and then the different cell lines were
compared between them.
Results
For these experiments, we selected two human breast can-
cer cell lines, MDA-MB-231 cells that are highly aggressive
and MCF-7 cells that are less aggressive, and a breast-
derived cell line, MCF-10A cells that are non-tumoral [27].
First, we determined the sensitivity of the three human
breast-derived cells to doxorubicin by evaluating their
survival and synthesis of DNA and proteins after a 3-day
exposure to the drug (Fig. 1A). Doxorubicin dose depen-
dently reduced cell survival in all three cells (Fig. 1Aa).
From these results, we selected two doxorubicin concen-
trations for further experiments, 100 nM, representing the
mean plasma concentration of doxorubicin in patients under
chemotherapy [3], and a tenfold lower concentration,
10 nM. At 100 nM doxorubicin, DNA synthesis was abol-
ished in all three cells, whereas at 10 nM, the decrease in
DNA synthesis was more apparent in MDA-MB-231 and
MCF-10A cells than in MCF-7 cells (Fig. 1Ab). Cells were
dose dependently sensitive to the drug for inhibition of
protein synthesis, but at a lesser level than of DNA synthesis
(Fig. 1Ac). Then, we performed a time-course evaluation of
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Fig. 1 Effect of doxorubicin and quercetin on cell survival and DNA
and protein synthesis. A, a Human MDA-MB-231 and MCF-7 breast
cancer cells and non-tumoral MCF-10A breast-derived cells were
exposed for 72 h to a increasing concentrations of doxorubicin (5, 10,
50, and 100 nM) and then the MTT assay was performed: MDA-MB-
231 cells (filled square), MCF-7 cells (filled diamond), MCF-10A
cells (open circle); b doxorubicin (DOX) (100 nM, black bars or
10 nM, stripped bars), and then 3H-thymidine incorporation (3H-T)
was performed to evaluate DNA synthesis; and c doxorubicin (DOX)
(100 nM, black bars or 10 nM, stripped bars), and then 3H-leucine
incorporation (3H-Leu) was performed to evaluate protein synthesis.
Results are the means ± SD of quadruplicates of two independent
experiments. Treated cells were compared with untreated cells using a
Student’s t test: *P \ 0.05; **P \ 0.01; ***P \ 0.001. B Human
MDA-MB-231 (filled square) and MCF-7 breast cancer cells (filled
diamond) and non-tumoral MCF-10A breast-derived cells (open
circle) were exposed to increasing concentrations of quercetin for
24 h (d), 48 h (e), or 72 h (f), and then the MTT assay was performed.
Results are the means ± SD of quadruplicates of two independent
experiments. Treated cells were compared with untreated cells using a
Student’s t test: *P \ 0.05; **P \ 0.01; ***P \ 0.001
Cancer Chemother Pharmacol (2011) 68:1161–1172 1165
123
cell sensitivity to quercetin (Fig. 1B). Cell survival was
little affected by quercetin after 24 h (Fig. 1Bd); however,
after 48 and 72 h, quercetin dose dependently decreased
survival in both tumor cells, MDA-MB-231 cells respond-
ing more and more rapidly than MCF-7 cells to the drug
(Fig. 1Be, Bf). From this information, we selected 5 and
10 lM quercetin corresponding to slightly lower and higher
quercetin concentration compared with the IC50 (9 lM) of
quercetin for the most sensitive cells.
For further drug combination studies, we exposed the
cells for 72 h to each drug alone or to combinations of 10
nM and 100 nM doxorubicin and 5 lM and 10 lM quer-
cetin, respectively. First, we determined the sensitivity of
the three human breast-derived cells to drug combinations
by evaluating their survival and the synthesis of DNA and
proteins after a 3-day cell exposure to the drug (Fig. 2). In
MCF-7 and MCF-10A cells, quercetin was less efficient
than doxorubicin and did not enhance doxorubicin cyto-
toxic effects (Fig. 2A). In MDA-MB-231 cells, 10 lM
quercetin was as cytotoxic as 100 nM doxorubicin and
enhanced doxorubicin effects, the combination of 10 nM
doxorubicin and 10 lM quercetin being as cytotoxic as
100 nM doxorubicin. Quercetin alone dose dependently
inhibited DNA synthesis more in MDA-MB-231 cells than
in the other cells and in combination with doxorubicin
enhanced doxorubicin effects in MCF-7 cells (Fig. 2B).
Quercetin dose dependently inhibited protein synthesis and
in combination enhanced doxorubicin effects in tumor
cells, but not in non-tumoral cells (Fig. 2C).
Then, we determined whether oxidative stress may be
involved in these effects by evaluating ROS production by
cells, thiol content in cells or GST activity and expression
by cells. No changes in ROS production by either of the
three cell lines were observed following cell exposure to
doxorubicin and quercetin, or their combination for 24 or
72 h (data not shown). Quercetin did not modulate cellular
thiols levels in MCF-7 cells and dose dependently
increased cellular thiol levels in MDA-MB-231 and MCF-
10A cells; however, quercetin could compensate for
doxorubicin-induced decreased levels of cellular thiols in
non-tumoral cells (Fig. 3A). MCF-7 cells did not express
GST activity or GST-P1-1 protein (results not shown),
confirming previous information [28], and GST expression
was higher in MCF-10A than in MDA-MB-231 cells. Only
in MDA-MB-231 cells did quercetin, but not doxorubicin,
decreased GST activity (Fig. 3B), but not GST-P1-1 pro-
tein determined by western blot (results not shown).
We also determined whether quercetin may modulate
cellular tyrosine phosphorylation pathways and drug-
induced DNA damage in human mammary tumor and non-
tumoral cells. In MDA-MB-231 cells, quercetin decreased
tyrosine phosphorylation of a major 75-kDa protein that
was maintained in combination with doxorubicin. In
MCF-10A cells, quercetin increased tyrosine phosphory-
lation of a major 55-kDa protein which was also main-
tained in combination with doxorubicin (Fig. 4A). No
major band of tyrosine phosphorylated proteins was found
in MCF-7 cells (not shown). In all three cells, doxorubicin
induced high amount of DNA strand breaks, whereas
quercetin alone did not. Combination of quercetin with
doxorubicin reduced DNA damage more in non-tumoral
cells than in tumor cells (Fig. 4B).
Then, we evaluated whether the migratory potential of
tumor cells may be affected more by drug combinations
than each drug alone, either after short-term exposure (8 h)
or long-term exposure (72 h) (Fig. 5). Both drugs and their
combination significantly diminished breast tumor cell
migration, and quercetin additively potentiated doxorubicin
effects (Fig. 5 upper panels). However, the migratory
potential of MDA-MB-231 cells was higher than the
migratory potential of MCF-7 cells at both times (Fig. 5
lower panels). Following cell exposure to the drugs or their
combinations, cytoskeletal actin expression and cellular
localization was evaluated using fluorescent phalloidin. In
MCF-7 cells (Fig. 6A), doxorubicin did not interfere with
cytoskeletal actin, while quercetin induced a weak frag-
mentation of actin at the cell membrane, which was
enhanced by drug combination. In MDA-MB-231 cells
(Fig. 6B), doxorubicin induced a decrease in the ratio of
cytoplasm-to-nucleus sizes, whereas quercetin as single
agent as well as its combination with doxorubicin induced
cell polynucleation, a never-reported finding (Fig. 6B,
arrowheads). The drugs either as single agents or their
combination did not modify cytoskeletal actin of MCF-
10A cells (Fig. 6C). Doxorubicin induced heterogeneity of
the size of the nuclei in all three cells.
Discussion
Our aims are to evaluate new chemotherapeutic combina-
tions based on the anthracycline doxorubicin, an essential
component of combination chemotherapies for the treat-
ment of breast cancer, however, displaying toxicity for
normal cells [3, 4]. Most breast cancer patients with
advanced disease treated with present combination thera-
pies have only temporary responses to treatment, associ-
ated with reduced quality of life due to the side effects of
the therapies. Thus, improved therapeutic regimens able to
potentiate doxorubicin effects, allowing decreasing the
dose of this agent, together with protecting non-tumoral
cells against the non-specific cytotoxic effects of doxoru-
bicin for these cells, are needed to improve treatment of
breast cancer patients. In vitro and in animal models of
cancer, several natural products including quercetin
improved the therapeutic index of doxorubicin [22–24]. In
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Fig. 2 Effect of a 3-day exposure to doxorubicin–quercetin combi-
nation on cell survival and DNA and protein synthesis. Human MDA-
MB-231 and MCF-7 breast cancer cells and non-tumoral MCF-10A
breast-derived cells were exposed to doxorubicin (DOX) (100 nM,
left panels, or 10 nM, right panels) and quercetin (QUE) (5 or 10 lM)
as single agents or in combination for 72 h, then A the MTT test to
measure cell survival or B 3H-thymidine incorporation (3H-T) to
quantify DNA synthesis, or C 3H-leucine incorporation (3H-Leu)
to quantify protein synthesis was performed. Results are the
means ± SD of quadruplicates of two independent experiments.
Treated cells were compared with untreated cells using a Student’s
t test: *P \ 0.05; **P \ 0.01; ***P \ 0.001
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murine models of cancer, combination of dietary quercetin
and intratumoral injection of doxorubicin was able to
synergistically reduce tumor volume and metastatic spread
[23]. Quercetin was previously shown to be able to also
reduce in vitro the toxicity of doxorubicin by inhibiting the
catalytic activity of enzymes involved in doxorubicin
biotransformation [3, 24]. Therefore, we evaluated some of
the effects and cellular mechanisms of doxorubicin–quer-
cetin combination in human breast cancer cells of
increasing aggressiveness, the poorly metastatic MCF-7
cells and the highly metastatic MDA-MB-231 cells com-
pared with human non-tumoral MCF-10A mammary cells
[27]. In human plasma, the peak and the steady-state
concentrations of doxorubicin are 5 lM and 25–250 nM,
respectively [3, 29]. Therefore, for these experiments, we
selected doses of doxorubicin representing relevant plasma
levels in patients treated with doxorubicin, and a tenfold
lower dose to evaluate combination effects.
The mechanisms of action of anthracyclines in cancer
cells are controversial. Doxorubicin is thought to bind and
cross-link DNA and to intercalate between bases and thus
to inhibit DNA, RNA, and protein synthesis. Doxorubicin
inhibits topoisomerase II, essential enzymes that act by
introducing or removing DNA superhelical tensions, tying
or untying DNA knots and catenating or decatenating cir-
cular DNA [29, 30], thus initiating DNA damage and cell
apoptosis. Type I DNA topoisomerases introduce transient
single-strand DNA breaks, while type II DNA topoisome-
rases introduce transient DNA double-strand breaks.
Doxorubicin inhibits the topoisomerase II by locking onto
the 50-end of the DNA molecule, inducing DNA breaks
[29]. Tumor cells that are resistant to the anthracyclines
have reduced levels or altered activity of this enzyme, with
a concomitant reduction of DNA strand breaks. Doxoru-
bicin has been shown to induce the generation of free
radicals and oxidative DNA damage in both malignant and
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Fig. 3 Effects of a 3-day exposure to doxorubicin, quercetin or
doxorubicin–quercetin combinations on cellular thiol content and
GST activity. A Human MDA-MB-231 and MCF-7 breast cancer
cells and non-tumoral MCF-10A breast-derived cells were exposed
for 72 h to either doxorubicin (DOX) (100 nM, left panel or 10 nM,
right panel) or quercetin (5 or 10 lM) as single agents or in
combination, and then the thiol content of cell lysates was determined
using a monobromobimane assay. Results are the means ± SD of
triplicates of three independent experiments. Treated cells were
compared with untreated cells using a Student’s t test: *P \ 0.05;
**P \ 0.01; ***P \ 0.001. B Human MDA-MB-231 breast cancer
cells (left panel) or MCF-10A non-tumoral breast-derived cells (right
panel) were exposed to 10 nM doxorubicin (DOX), 10 lM quercetin,
or a combination of both for 72 h, and then GST activity (nM of
CDNB-GSH/min/mg of proteins) was evaluated in cell extracts.
Results are the means ± SD of triplicates of three independent
experiments. Treated cells were compared with untreated cells using a
Student’s t test: *P \ 0.05; **P \ 0.01; ***P \ 0.001. CDNB,
1-chloro-2,4-dinitrobenzene; NT non-treated
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non-malignant cells [3, 4, 29–31], resulting in lipid per-
oxidation and altered levels of GSH or of the enzymes of
the GSH redox pathway [19]. Other possible mechanisms
may also explain the cytotoxicity of anthracyclines, such as
interference with microtubule polymerization and cell
cytoskeleton, or modulation of PKCd activity [29, 32].
Alternatively to cell death, anthracyclines can induce
growth arrest in the G2 phase of the cell cycle [3].
As expected from previous information, doxorubicin as
a single agent dose dependently reduced cell survival of all
three human breast-derived cells, tumor cells as well as
non-tumoral cells. Doxorubicin dose dependently also
reduced DNA and protein synthesis and this reduction was
cell type dependent. Previous studies have shown that
quercetin dose dependently suppressed growth, DNA,
RNA, and protein synthesis of breast cancer cells by
increasing the expression of connexin proteins and modi-
fying cell morphology [8, 33]. As a single agent, quercetin
dose dependently decreased tumor cell survival of both
MCF-7 and MDA-MB-231 cells, the most aggressive cells
responding more than the less aggressive cells and the non-
tumoral cells. Quercetin dose dependently also inhibited
DNA and protein synthesis, enhancing doxorubicin effects
in tumor cells, but not in non-tumoral cells. In agreement
with our results, previous reports have shown that quercetin
can interfere with cancer cell metabolism and proliferation
[9, 34–36]. In addition, we show that quercetin enhanced
doxorubicin cytotoxic effects in tumor cells but that the
non-specific effects are much less marked for non-tumoral
than for tumor cells. The anticancer effects of quercetin
have been attributed to the inhibition of enzymes that
activates carcinogenesis, antioxidant activity, modification
of signal transduction pathways and interaction with
receptors and other proteins [8, 36–38]. In our experiments,
no changes in ROS production by either of the three cells
were observed; however, quercetin was able to compensate
for doxorubicin-induced decrease in cellular thiols, in
particular in non-tumoral cells, without important modifi-
cation of GST activity or GST-P1-1 expression. Moreover,
quercetin modified the tyrosine phosphorylation of cellular
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Fig. 4 Effects of doxorubicin and quercetin on cellular protein
tyrosine phosphorylation and DNA strand breaks. A Human MDA-
MB-231 breast cancer cells (left panel) or MCF-10A non-tumoral
breast-derived cells (right panel) were exposed to 10 nM doxorubicin
(DOX), 10 lM quercetin, or a combination of both for 72 h, and then
cell protein phosphorylation was determined by western blot in cell
extracts using a phosphotyrosine protein-specific antibody. B Human
MCF-7, MDA-MB-231 breast cancer cells and non-tumoral breast-
derived MCF-10A cells were exposed for 72 h to 10 nM doxorubicin
(DOX), 10 lM quercetin (QUE), or their combinations, and then the
Comet assay was performed to evaluate DNA strand breaks. Results
are expressed as the fold-increase score of damaged DNA of treated
cells compared with untreated cells and are the means ± SD of
duplicates of two independent experiments. Treated cells were
compared with untreated cells using a Student’s t test: *P \ 0.05;
**P \ 0.01; ***P \ 0.001
Cancer Chemother Pharmacol (2011) 68:1161–1172 1169
123
proteins differently in tumor cells than in non-tumoral cells
and these changes were maintained in combination with
doxorubicin, suggesting a major role of quercetin in protein
kinase pathways in tumor cells and non-tumoral cells.
Kinase pathways, such as the mitogen-activated protein
kinase, 1-phosphatidylinositol kinase, and the src protein
kinase pathways, are also cellular targets of quercetin [16,
39–41]. In breast cancer cells, quercetin was previously
shown to block the translocation of the PKCd protein from
the cytosol to the membrane inhibiting the transduction of
the PKCd signaling pathway [42]. We show that quercetin
potentiated doxorubicin effects in diminishing breast tumor
cell migration, and in cell-selectively modifying doxoru-
bicin effects on cytoskeletal actin, suggesting an effect on
cell cytoskeleton assembly, cytoplasm size, and cell po-
lynucleation, a up to now never-reported effect of quer-
cetin. Combination of quercetin with doxorubicin reduced
DNA strand breaks and damage more in non-tumoral cells
than in tumor cells, thus suggesting a protective role of
quercetin.
In summary, our results have shown that combining
doxorubicin with quercetin may be very interesting for
chemotherapy of human breast cancer, and possibly of
other human cancers based on doxorubicin, since this
molecule can enhance the toxic effects of doxorubicin in
breast cancer cells and reduce the side effects of doxoru-
bicin in non-tumoral cells. This combination also allows
reaching an anticancer efficacy with lower doses of doxo-
rubicin comparable to the effect achieved with higher
doses, and thus decreasing cytotoxic effects of high doses
of doxorubicin for normal cells. We hypothesize that the
selectivity of quercetin for highly aggressive cancer cells is
due to its properties as a tyrosine protein kinase inhibitor.
However, the limitation of using quercetin in human
therapy is the high dose of this agent necessary to achieve
efficacy. Thus, it will be necessary to better understand the
molecular and cellular mechanisms of quercetin and its
chemical characteristics, which may be improved to
develop new cancer-specific drugs.
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